glofitamab as a soc in third-line dlbcl and its potential in earlier lines of therapy
Published 1 year ago • 269 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:08
the current and future role of bispecifics in r/r dlbcl: epcoritamab, glofitamab & more
-
2:21
impact of tmtv on pfs following glofitamab treatment in r/r dlbcl
-
2:40
phase ii study of glofitamab in patients with r/r lbcl
-
2:33
glofitamab as a single agent in heavily pretreated patients with dlbcl
-
19:10
hemophagocytic lympho-histiocytosis (hlh)
-
11:49
label-free quantification of chemotherapeutic cytotoxicity in glial cells
-
10:42
gene set analysis of gwas with magma in omicsbox
-
7:16
changes in the classification of dlbcl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
7:48
glofitamab, a cd20/cd3 bispecific antibody, in the treatment of r/r dlbcl
-
6:12
coalition: glofitamab r-chop or glofitamab pola-r-chp in patients with high-risk dlbcl
-
1:58
ash highlights: glofitamab in dlbcl & pirtobrutinib and epcoritamab in richter's transformation
-
1:46
phase i study of costimulatory bispecific antibody ro7227166 combined with glofitamab in r/r b-nhl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:43
insights into phase i/ii study assessing fixed-duration glofitamab treatment for r/r lbcl
-
2:04
the starglo trial: glofitamab in combination with gemcitabine and oxaliplatin in r/r dlbcl
-
5:30
glofitamab in r/r dlbcl: updated safety and efficacy data
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
3:48
coalition: glofitamab r-chop or glofitamab pola-r-chp in high-risk dlbcl
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
1:45
a phase i/ii trial of glofitamab monotherapy in r/r mcl